Search Results

• • 4 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.

  Authors:Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini, Davide Ciardiello, Valentina Belli, Nunzia Matrone, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  Jan. 28, 20195,744 words Report 1620LBackground Previous studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to prevent the onset of resistance to anti-EGFR monoclonal antibodies in KRAS-wild type...

• Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

  Authors:Valentina Belli, Nunzia Matrone, Stefania Napolitano, Giorgia Migliardi, Francesca Cottino, Andrea Bertotti, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  June 4, 20197,723 words Report 1610LBackground Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is an effective treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC)....

• Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.

  Authors:Pietro Paolo Vitiello, Giulia Martini, Luigi Mele, Emilio Francesco Giunta, Vincenzo De Falco, Davide Ciardiello, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 40, Issue 1) Peer-Reviewed

  Jan. 6, 20216,929 words Article 1650LBackground Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of...

• Dual inhibition of TGF[beta] and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.

  Authors:Davide Ciardiello, Bernadette Blauensteiner, Nunzia Matrone, Valentina Belli, Thomas Mohr, Pietro Paolo Vitiello, et al.From:Medical Oncology (Vol. 38, Issue 3) Peer-Reviewed

  Mar. 2021360 words Report, Brief articl...

   Abstract Only